Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model

T R Kreil, M M Eibl, T R Kreil, M M Eibl

Abstract

Antibody-dependent enhancement of flavivirus infection, which except for dengue virus is without clear proof in vivo, is still under debate. Recently, postexposure immunoglobulin prophylaxis against tick-borne encephalitis virus, a flavivirus, was claimed to possibly have worsened the outcome of infection due to antibody-dependent enhancement. In the present study, antibody-dependent enhancement and pre- or postexposure protection by passive administration of tick-borne encephalitis virus immunoglobulin were evaluated in a mouse model. Preexposure treatment with homologous murine or heterologous human immunoglobulin provided complete protection against lethal challenge with tick-borne encephalitis virus. For postexposure treatment with antibody, the degree of protection correlated with the amount of immunoglobulin administered and was inversely related to the time interval between infection and treatment. Indications of enhancement of infection would have been increased lethality or reduced mean survival time, but neither was observed under the conditions used in our experiments despite the broad range of immunoglobulin and virus challenge doses applied. In contrast to these in vivo results, antibody-dependent enhancement of tick-borne encephalitis virus infection of murine peritoneal macrophages was readily demonstrable in vitro. Thus, antibody-dependent enhancement of viral infection in vitro does not necessarily predict enhancement in vivo.

References

    1. Ann Intern Med. 1991 Jan 15;114(2):119-27
    1. Nature. 1981 Jan 15;289(5794):189-91
    1. Virology. 1983 Apr 30;126(2):525-37
    1. J Med Virol. 1980;6(3):213-21
    1. Schweiz Med Wochenschr. 1994 Oct 22;124(42):1837-40
    1. Acta Virol. 1991 May;35(3):218-25
    1. J Med Virol. 1980;6(2):103-9
    1. Rev Infect Dis. 1989 May-Jun;11 Suppl 4:S830-9
    1. Arch Virol. 1987;93(3-4):295-301
    1. Curr Top Microbiol Immunol. 1968;43:44-91
    1. J Gen Virol. 1994 Sep;75 ( Pt 9):2399-402
    1. Bull World Health Organ. 1969;40(1):113-21
    1. Science. 1988 Oct 28;242(4878):580-3
    1. J Gen Virol. 1986 Feb;67 ( Pt 2):229-34
    1. Lancet. 1995 Dec 2;346(8988):1502
    1. Acta Virol. 1994 Jun;38(3):141-9
    1. J Gen Virol. 1985 Aug;66 ( Pt 8):1831-7
    1. J Gen Virol. 1986 Mar;67 ( Pt 3):591-5
    1. Zentralbl Bakteriol Orig. 1959 Apr;174(5-6):440-56
    1. Annu Rev Immunol. 1991;9:457-92
    1. J Gen Virol. 1989 Jun;70 ( Pt 6):1605-8
    1. J Gen Virol. 1986 Nov;67 ( Pt 11):2539-42
    1. J Infect Dis. 1996 Jan;173(1):60-7
    1. J Med Virol. 1996 Jan;48(1):102-7
    1. Infect Immun. 1981 Jul;33(1):250-7
    1. Dysphagia. 1987;2(2):109-11
    1. J Infect Dis. 1974 Dec;130(6):634-41
    1. Wien Klin Wochenschr. 1981 Nov 13;93(21):665-7

Source: PubMed

3
購読する